Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Market Closed 03-20 16:00:00 EDT

72.22

-2.62

-3.50%

盘后72.22

+0.000.00%

18:14 EDT

High75.48	Low70.78	Vol837.54K
Open74.90	D1 Closing74.84	Amplitude6.28%
Mkt Cap2.07B	Tradable Cap1.90B	Total Shares28.69M
T/O61.00M	T/O Rate3.19%	Tradable Shares26.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":72.22,"timestamp":1774036800000,"preClose":74.84,"halted":0,"volume":837535,"hourTrading":{"tag":"盘后","latestPrice":72.22,"preClose":72.22,"latestTime":"18:14 EDT","volume":45817,"amount":3308803.486,"timestamp":1774044896504,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03500801710315345,"floatShares":26240400,"shares":28688000,"eps":-9.73,"marketStatus":"Market Closed","change":-2.62,"latestTime":"03-20 16:00:00 EDT","open":74.9,"high":75.48,"low":70.7792,"amount":60998963.8539,"amplitude":0.062811,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.73,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":74.84,"preHourTrading":{"tag":"盘前","latestPrice":75.96,"preClose":74.84,"latestTime":"09:25 EDT","volume":650,"amount":49240.49,"timestamp":1774013155951,"change":1.12,"changeRate":0.014965,"amplitude":0.040086},"postHourTrading":{"tag":"盘后","latestPrice":72.22,"preClose":72.22,"latestTime":"18:14 EDT","volume":45817,"amount":3308803.486,"timestamp":1774044896504,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0365259814589454,"impliedVol":0.8981,"impliedVolPercentile":0.352},"requestUrl":"/m/hq/s/NKTR/tweets","defaultTab":"tweets","newsList":[{"id":"2620734565","title":"Nektar rezpegaldesleukin Phase 2b data set for two oral presentations at AAD annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734565","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620734565?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:00","pubTimestamp":1774015247,"startTime":"0","endTime":"0","summary":"Nektar will attend the American Academy of Dermatology Annual Meeting on March 27-31, 2026 in Denver, Colorado.Data from a Phase 2b study of rezpegaldesleukin in severe-to-very-severe alopecia areata will be presented on March 28, 2026 from 10:36-10:48 AM MST at the Colorado Convention Center .Phase 2b data for rezpegaldesleukin in moderate-to-severe atopic dermatitis will be presented on March 28, 2026 from 11:40-11:45 AM MST at the Colorado Convention Center .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLZR438:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2620942347","title":"Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942347?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:15","pubTimestamp":1773742523,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on NKTR stock, giving a Buy rating today. Arthur He CFA has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-rezpeg-clinical-momentum-and-strong-cash-runway-underscore-attractive-risk‑reward-at-current-levels-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-rezpeg-clinical-momentum-and-strong-cash-runway-underscore-attractive-risk‑reward-at-current-levels-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007","CFA"],"gpt_icon":0},{"id":"2620428220","title":"Nektar initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428220?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:45","pubTimestamp":1773740728,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm initiated coverage of Nektar (NKTR) with a Buy rating and no price target The company is developing immunotherapies for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","BK4127","BK4566","NKTR","BK4007","BK4207","BK4585"],"gpt_icon":0},{"id":"2620428854","title":"Nektar Therapeutics : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428854?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:38","pubTimestamp":1773740313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN4040QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2620246051","title":"Nektar Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620246051?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:47","pubTimestamp":1773679620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:47 ET (16:47 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2619149111","title":"Nektar Therapeutics Bets Big on Respag Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2619149111","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619149111?lang=en_us&edition=fundamental","pubTime":"2026-03-14 08:04","pubTimestamp":1773446678,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (($NKTR)) has held its Q4 earnings call. Read on for the main highlights of the call. Nektar Therapeutics’ latest earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-bets-big-on-respag-phase-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-bets-big-on-respag-phase-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1131410982","title":"Stock Track | Nektar Therapeutics Soars 5.45% Intraday on Analyst Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1131410982","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131410982?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:33","pubTimestamp":1773408838,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) saw its stock price soar 5.45% during intraday trading on Friday, reflecting significant positive momentum.The surge appears to be driven by renewed analyst confidence in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"gpt_icon":0},{"id":"2619557881","title":"Nektar Therapeutics Q4 Swings to Loss, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2619557881","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619557881?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:31","pubTimestamp":1773347503,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  reported a Q4 loss late Thursday of $1.78 per diluted share, swinging from earnings of $0.52 a year earlier.Analysts surveyed by FactSet expected a loss of $2.47.Revenue for the three months ended Dec. 31 was $21.8 million, down from $29.2 million a year earlier.Analysts polled by FactSet expected $10.2 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"gpt_icon":0},{"id":"2619155206","title":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155206","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155206?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:27","pubTimestamp":1773347257,"startTime":"0","endTime":"0","summary":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"gpt_icon":0},{"id":"1178275171","title":"Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1178275171","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178275171?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:12","pubTimestamp":1773331959,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday. The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"gpt_icon":0},{"id":"2618137403","title":"Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2618137403","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618137403?lang=en_us&edition=fundamental","pubTime":"2026-03-12 22:01","pubTimestamp":1773324069,"startTime":"0","endTime":"0","summary":"Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10 and 20 of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL9rvqfr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2618367041","title":"Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618367041","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618367041?lang=en_us&edition=fundamental","pubTime":"2026-03-10 05:27","pubTimestamp":1773091640,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics recently faced multiple securities class action filings and investigations alleging misleading disclosures around enrollment protocols and outcomes in its REZOLVE-AA Phase 2b trial, which previously failed to reach statistical significance.\nThese legal challenges focus on whether management accurately represented the integrity of a key clinical program, raising fresh questions about governance, disclosure practices, and oversight of trial execution.\nWe’ll now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/will-rezolve-aa-class-actions-over-trial-disclosures-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/will-rezolve-aa-class-actions-over-trial-disclosures-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AA","BK4588","BK4007","NKTR","BK4153","LU2543165471.USD","BK4585"],"gpt_icon":0},{"id":"2617551146","title":"BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617551146","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617551146?lang=en_us&edition=fundamental","pubTime":"2026-03-07 07:07","pubTimestamp":1772838447,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 6 (Reuters) - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA7DQ4BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2617559126","title":"Nektar Therapeutics Reports 2025 Inducement Plan Stock Option Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2617559126","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617559126?lang=en_us&edition=fundamental","pubTime":"2026-03-07 07:00","pubTimestamp":1772838013,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics said its board’s Organization and Compensation Committee granted non-qualified stock options covering 4,300 shares to three newly hired employees under the company’s 2025 Inducement Plan. The options have an exercise price of $73.73 per share, an eight-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to continued employment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL9N9YHt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1140340721","title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 65.16%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1140340721","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140340721?lang=en_us&edition=fundamental","pubTime":"2026-03-05 11:43","pubTimestamp":1772682193,"startTime":"0","endTime":"0","summary":"Title Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 65.16%, and institutional views are bullish Abstract Nektar Therapeutics will report quarterly results on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 65.16%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2616484556","title":"Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2616484556","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616484556?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:20","pubTimestamp":1772634010,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL6g7Vh0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2616336069","title":"BTIG Keeps Their Buy Rating on Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336069","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336069?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:39","pubTimestamp":1772451568,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison maintained a Buy rating on Nektar Therapeutics today and set a price target of $151.00. According to TipRanks, Harriso...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"gpt_icon":0},{"id":"2614307748","title":"Nektar Therapeutics Schedules Fourth-Quarter and Full-Year Financial Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2614307748","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614307748?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:00","pubTimestamp":1772146822,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Schedules Fourth-Quarter and Full-Year Financial Results Call               Nektar Therapeutics will announce its fourth-quarter and full-year 2025 financial results on Thursday, M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL9HqgZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2614729715","title":"Nektar Therapeutics to Present at TD Cowen Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614729715","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614729715?lang=en_us&edition=fundamental","pubTime":"2026-02-25 07:00","pubTimestamp":1771974018,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics to Present at TD Cowen Annual Health Care Conference               Nektar Therapeutics said its management will participate in the TD Cowen 46th Annual Health Care Conference in Bo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL87bPNl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK7035","EVT.AU","BK4007"],"gpt_icon":0},{"id":"2613334717","title":"A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2613334717","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613334717?lang=en_us&edition=fundamental","pubTime":"2026-02-23 23:20","pubTimestamp":1771860034,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) shares are back in focus after the company announced a research collaboration with the University of California, San Francisco and MS expert Dr. Stephen Hauser to study its TNFR2 agonist antibody NKTR-0165.\nSee our latest analysis for Nektar Therapeutics.\nThe UCSF collaboration headlines a very strong run for Nektar, with a 30 day share price return of 98.68% and a year to date share price return of 69.81%. The one year total shareholder return is very large, and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-ucsf","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-ucsf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0141},{"period":"1month","weight":-0.0131},{"period":"3month","weight":0.5418},{"period":"6month","weight":0.3098},{"period":"1year","weight":4.5132},{"period":"ytd","weight":0.7081}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.00052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction